04/16/2018 | Press release | Distributed by Public on 04/16/2018 02:36
This collaboration means that GHP, through its business area Vårdsamverkan, will be responsible for ensuring that all of Trygg-Hansa's patients with orthopaedic or spine-related problems receive effective care of the highest quality.
'For us at Trygg-Hansa it is extremely important that our customers have access to the best possible quality of care and get the best possible service. The cooperation with GHP strengthens our ambition and we are pleased to now be able to start this joint journey,' says Pierre Schuster, Head of Corporate division at Trygg-Hansa.
This strategic collaboration means that GHP is responsible for all care of Trygg-Hansa's patients with musculoskeletal problems (knee, hip, shoulder, spine, hand or foot). In contrast with how health care is traditionally purchased, with the focus on cost per measure taken, this collaboration focuses on quality outcomes, preventive work, service and total health care costs for the population. Through the business area Vårdsamverkan, GHP is responsible for the purchase and control of all care, which is then provided by both GHP's own clinics and external clinics.
'This collaboration is incredibly exciting. For us it means that together with a good collaboration partner we can develop the full potential of Vårdsamverkan. When we focus on quality outcomes and entire care chains we can achieve considerable improvements in health care,' says Daniel Öhman, CEO of GHP.
Financially this means that sales in Vårdsamverkan will increase by SEK 40-60 million per year. Approximately 30% of these sales already exist today in GHP's clinics, and this percentage is expected to increase from the collaboration. For GHP Vårdsamverkan, the agreement is not expected to have any major positive effect during 2018 as investments in IT, process and general business development are planned. Profitability in the clinics from additional sales is expected to be in line with existing profit margins. The agreement is effective as of 1 July 2018.
16 April 2018
GHP Specialty Care AB (publ)
Queries should be addressed to:
Daniel Öhman, CEO, Tel: +46 708 55 37 07
GHP is an internationally active health care provider that operates specialist clinics in a select number of diagnostic areas through the application of a business model that is unique in the health care industry, where leading doctors and medical staff become partners and shareholders. Each clinic specialises in a particular patient group, and this leads to increased efficiency and higher quality. This is the cornerstone of GHP's business philosophy - 'Quality through specialisation'. GHP shares are traded on the Small Cap list of Nasdaq Stockholm under the ticker symbol 'GHP'.
GHP Specialty Care AB (publ) | Corp. ID No. 556757-1103
Södra Hamngatan 45 | SE-411 06 Gothenburg | Sweden
Tel +46-31 712 53 00 | Fax +46-31 313 13 21 | www.ghp.se
GHP Specialty Care AB (publ) is required to publish the information herein pursuant to the EU Market Abuse Regulation. This information was published, through the agency of the contact persons set out above, on 16 April 2018 at 10:30 a.m. CET.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Denna information skickades av Cision http://newsroom.cision.com
Följande filer finns för nedladdning: